Top
Begin typing your search above and press return to search.
keyboard_arrow_down
Login
exit_to_app
Stan Swamy needs a straw to drink water
access_time 2020-11-28T15:41:03+05:30
The unwritten gospel of Argentina
access_time 2020-11-27T17:18:41+05:30
The soccer wizard with a political streak
access_time 2020-11-27T11:28:29+05:30
General strike should be a wake-up call
access_time 2020-11-25T11:21:39+05:30
Fearless journalism
access_time 2020-11-23T16:08:15+05:30
exit_to_app
Homechevron_rightBusinesschevron_rightLupin launches chronic ...

Lupin launches chronic angina treatment drug in the US

text_fields
bookmark_border
Lupin launches chronic angina treatment drug in the US
cancel

New Delhi: Drug maker Lupin Thursday announced exclusive launch of Ranolazine extended-release (ER) tablets, indicated for the treatment of chronic angina, in the US market.

The newly launched product, in strengths of 500 mg and 1,000 mg, is a generic version of Gilead Sciences' Ranexa ER tablets, Lupin said in BSE filing.

Quoting IQVIA MAT December 2018 data, Lupin said Ranolazine ER tablets, 500 mg and 1,000 mg had an annual sales of approximately USD 945 million in the US.

"This is a meaningful product and further strengthens our portfolio of generic products in the US. Launching exclusive and semi-exclusive generics is an important stepping stone as we transition to more complex generics," Lupin Managing Director Nilesh Gupta said.

"Products like Ranolazine bring significant savings to US consumers and are a key part of our vision to bring exclusive high quality, affordable medicines to the market, he added.

Shares of Lupin were trading 0.29 per cent up at Rs 769.95 apiece on BSE.

Show Full Article
TAGS:
Web Title - Lupin launches chronic angina treatment drug in the US
Next Story